Trial Profile
Bioavailability of BI 1356 After Single Oral Administration of 5 mg BI 1356 Given as Tablet Formulation TF IIb Relative to Tablet Formulation TF II and Tablet Formulation iFF in Healthy Male Volunteers (an Open Label, Randomised, Single-dose, Three-way Crossover Study)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Linagliptin (Primary)
- Indications Diabetic nephropathies; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 17 Jul 2014 New trial record